Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Левитра: многогранность действия, перспективы применения
Левитра: многогранность действия, перспективы применения
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Варденафил (Левитра) – ингибитор фосфодиэстеразы типа 5, традиционно используемый для лечения эректильной дисфункции. Применение Левитры при сочетанной, особенно кардиоваскулярной, патологии, а также в комбинированной терапии, безопасно, однако изучено не в полной мере. Перспективы применения Левитры при лечении различных соматических заболеваний достаточно широки.
Ключевые слова: Левитра, варденафил, эректильная дисфункция, безопасность, сердечно-сосудистый.
Key words: Levitra, vardenafil, erectile dysfunction, safety, cardiovascular.
Ключевые слова: Левитра, варденафил, эректильная дисфункция, безопасность, сердечно-сосудистый.
________________________________________________
Key words: Levitra, vardenafil, erectile dysfunction, safety, cardiovascular.
Полный текст
Список литературы
1. Porst H, Sharlip I. History and epidemiology of male sexual dysfunction. Standart practice in sexual medicine. Ed. Porst H And Buvat J 2006: 43–8.
2. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453–9.
3. Van Ahlen H, Zumbé J, Stauch K, Hanisch JU. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7 (9): 3161–9.
4. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006; 2 (4): 447–55.
5. Rosen RC, Jackson G, Kostis JB. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7 (6): 490–6.
6. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007; 14 (20): 2181–91.
7. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6 (3): 658–74.
8. Szabó G, Radovits T, Veres G et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009; 36 (4): 657–64.
9. Kapur V, Chien CV, Fuess JE, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008; 9 (3): 187–95.
10. Li HJ. Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension. Zhonghua Nan Ke Xue 2006; 12 (10): 953–6.
11. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005 26; 96 (12B): 32–36M.
12. Miner MM, Barnes A, Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010; 7 (5): 1937–47.
13. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; 24 (1): CD002187.
14. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I; Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3 (6): 1037–4.
15. Schwarz ER, Kapur V, Rodriguez J, Rastogi S et al. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007; 19 (2): 139–48.
16. Aizawa K, Hanaoka T, Kasai H et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29 (2): 123–8.
17. Deibert P, Schumacher YO, Ruecker G, Opitz OG et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver – results of a pilot study. Aliment Pharmacol Ther 2006 1; 23 (1): 121–8.
18. Cheon YK, Cho YD, Moon JH et al. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009; 69 (6): 1111–6.
19. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008; 31 (9): 799–808.
20. Ng CF, Wong A, Cheng CW et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic sy1. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005; 96 (12B): 42–6M.
22. Shabsigh R. The role of testosterone in the cavernous tissues and its neural supply. World J Urol 1997; 15: 21–6.
23. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7 (1): 46–56.
24. Van der Made F, Bloemers J, Yassem WE et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009; 6 (3): 777–90.
2. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453–9.
3. Van Ahlen H, Zumbé J, Stauch K, Hanisch JU. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7 (9): 3161–9.
4. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006; 2 (4): 447–55.
5. Rosen RC, Jackson G, Kostis JB. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7 (6): 490–6.
6. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007; 14 (20): 2181–91.
7. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6 (3): 658–74.
8. Szabó G, Radovits T, Veres G et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009; 36 (4): 657–64.
9. Kapur V, Chien CV, Fuess JE, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008; 9 (3): 187–95.
10. Li HJ. Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension. Zhonghua Nan Ke Xue 2006; 12 (10): 953–6.
11. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005 26; 96 (12B): 32–36M.
12. Miner MM, Barnes A, Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010; 7 (5): 1937–47.
13. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; 24 (1): CD002187.
14. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I; Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3 (6): 1037–4.
15. Schwarz ER, Kapur V, Rodriguez J, Rastogi S et al. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007; 19 (2): 139–48.
16. Aizawa K, Hanaoka T, Kasai H et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29 (2): 123–8.
17. Deibert P, Schumacher YO, Ruecker G, Opitz OG et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver – results of a pilot study. Aliment Pharmacol Ther 2006 1; 23 (1): 121–8.
18. Cheon YK, Cho YD, Moon JH et al. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009; 69 (6): 1111–6.
19. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008; 31 (9): 799–808.
20. Ng CF, Wong A, Cheng CW et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic sy1. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005; 96 (12B): 42–6M.
22. Shabsigh R. The role of testosterone in the cavernous tissues and its neural supply. World J Urol 1997; 15: 21–6.
23. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7 (1): 46–56.
24. Van der Made F, Bloemers J, Yassem WE et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009; 6 (3): 777–90.
Авторы
А.Л.Вёрткин, Л.Ю.Моргунов, Е.И.Звягинцева
ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ
Moscow State University of Medicine and Dentistry, Russian Agency for Health Care
ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ
________________________________________________
Moscow State University of Medicine and Dentistry, Russian Agency for Health Care
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.